natgillin/translations-raw huggingface dataset:
It is used in patients whose disease has spread locally or to other parts of the body and who have previously been treated with other cancer medicines (chemotherapy).
Zdravilo Nivolumab BMS se uporablja pri bolnikih, pri katerih se je rak razširil lokalno ali na druge dele telesa, in pri bolnikih, ki so se predhodno zdravili z drugimi zdravili za zdravljenje raka (kemoterapija).
For the full list of all side effects and restrictions with Nivolumab BMS, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Nivolumab BMS glejte navodilo
For practical information about using Nivolumab BMS, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Nivolumab BMS naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The recommended dose is 3 mg of nivolumab per kilogram body weight given into a vein over 60 minutes, every two weeks for as long as the patient continues to benefit from it. Doses may need to be delayed or treatment stopped altogether if the patient develops certain severe side effects.
Priporočeni odmerek je 3 mg nivolumaba na kilogram telesne mase, ki se v 60 minutah vsaka dva tedna injicira v veno, dokler zdravljenje bolniku koristi.
What is Nivolumab BMS and what is it used for?
Kaj je zdravilo Nivolumab BMS in za kaj se uporablja?
The antigen to which nivolumab has been designed to attach is a receptor called ‘programmed cell death-1' (PD-1), which switches off the activity of certain cells of the immune system (the body's natural defences) called T cells.
Antigen, za vezavo na katerega je bil izdelan nivolumab, je receptor, imenovan „programirana celična smrt-1“ (PD-1), ki izklopi dejavnost nekaterih celic imunskega sistema (naravne obrambe telesa), imenovanih celice T. Ko se nivolumab veže na PD-1, zavira ta receptor in mu prepreči izklop celic imunskega sistema.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nivolumab BMS, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is not intended to provide practical advice on how to use Nivolumab BMS.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What benefits of Nivolumab BMS have been shown in studies?
Kakšne koristi je zdravilo Nivolumab BMS izkazalo v študijah?
The European Commission granted a marketing authorisation valid throughout the European Union for Nivolumab BMS on 20.
Evropska komisija je dovoljenje za promet z zdravilom Nivolumab BMS, veljavno po vsej Evropski uniji,
What are the risks associated with Nivolumab BMS?
Kakšna tveganja so povezana z zdravilom Nivolumab BMS?
Most will resolve following appropriate treatment or on stopping Nivolumab BMS.
Večina učinkov izzveni po ustreznem zdravljenju ali prekinitvi uporabe
Side effects were considered manageable with appropriate measures and were outweighed by the benefits.
Koristi zdravljenja odtehtajo neželene učinke, ki ob ustreznih ukrepih veljajo za obvladljive.
The medicine was associated with improved survival over docetaxel in patients with advanced, previously treated squamous NSCLC, a patient group who have few treatment options.
Zdravilo je bilo v primerjavi z docetakselom povezano z izboljšanim preživetjem bolnikov z napredovalim, predhodno zdravljenim ploščatoceličnim nedrobnoceličnim pljučnim rakom, tj. skupino bolnikov, za katero je na voljo malo možnosti zdravljenja.
Nivolumab BMS can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the treatment of cancer.
Izdaja zdravila Nivolumab BMS je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki
Why is Nivolumab BMS approved?
Zakaj je bilo zdravilo Nivolumab BMS odobreno?
The medicine contains the active substance nivolumab.
Zdravilo Nivolumab BMS vsebuje zdravilno učinkovino nivolumab.
How is Nivolumab BMS used?
Kako se zdravilo Nivolumab BMS uporablja?
Nivolumab BMS have been shown to improve patients' survival in one main study involving 272 patients with previously treated squamous NSCLC that was advanced or had spread throughout the body.
V eni glavni študiji, ki je vključevala 272 bolnikov s predhodno zdravljenim ploščatoceličnim nedrobnoceličnim pljučnim karcinomom, ki je napredoval ali se razširil po telesu, so dokazali, da je zdravilo Nivolumab BMS izboljšalo preživetje bolnikov.
How does Nivolumab BMS work?
Kako zdravilo Nivolumab BMS deluje?
In addition, the company that markets Nivolumab BMS will provide educational packs for doctors who are expected to prescribe the medicine, containing information on how it should be used and how to manage side effects, particularly side effects related to the activity of the immune system.
Ti kompleti bodo vsebovali informacije o načinu uporabe zdravila in obvladovanju neželenih učinkov, predvsem neželenih učinkov, povezanih z dejavnostjo imunskega sistema.
Intravenous use Vial (glass) 15 ml (20 mg/ml) 1 vial
15 ml (20 mg/ml) 1 viala
300mg Concentrate for solution for infusion
300 mg Koncentrat za pripravo raztopine za infundiranje
(Invented) name Strength Pharmaceutical form
Številka postopka EMA (Izmišljeno) ime Jakost Farmacevtska oblika
This is the indication currently proposed by the applicant and has been registered in 15 member states of the EU.
To je indikacija, ki jo trenutno predlaga predlagatelj in je bila registrirana v 15 državah članicah EU.
You may need urgent medical attention or hospitalisation.
Lahko da potrebujete nujno zdravniško pomoč ali zdravljeje v bolnišnici.
Therefore the CHMP considered that this indication is acceptable.
Zato je bil CHMP mnenja, da je ta indikacija sprejemljiva.
Use in children and adolescents (< 18 years)
Uporaba pri otrocih in mladostnikih (< 18 let)
High Blood Pressure
Visok krvni tlak
1407 Sofia
1407 Sofija
Clinical and biological monitoring is required.
Potrebno je spremljanje kliničnih in bioloških parametrov.
Most older patients require the same dose as younger patients.
Večina starejših bolnikov potrebuje enak odmerek kot mlajši bolniki.
At least 61 percent of the oral dose is eliminated unchanged within 24 hours.
Vsaj 61 % peroralnega odmerka se izloči nespremenjenega v 24 urah.
This effect is thought to be a result of the complimentary actions of both components.
Domnevajo, da je ta učinek posledica komplementarnega delovanja obeh učinkovin.
The clinical consequences of these interactions have not been evaluated.
Klinični pomen teh interakcij ni bil ovrednoten.
The volume of distribution of losartan is 34 liters.
Volumen porazdelitve losartana je 34 litrov.
• if you are, think you may be or are planning to become pregnant (see also “Pregnancy and breast-feeding”)
• če ste noseči, mislite, da ste noseči, ali če nameravate zanositi (glejte tudi poglavje "Nosečnost in dojenje").
Consequently, there is thus no increase in bradykinin-mediated undesirable effects.
Posledično ne potencira z bradikininom povezanih neželenih učinkov.
This is a serious but rare side effect, which affects more than 1 out of 10,000 patients but fewer than 1 out of 1,000 patients.
To je resen vendar redek neželeni učinek, ki prizadane več kot 1 od 10.000 bolnikov, vendar manj kot 1 od 1.000 bolnikov.
There is no experience in children and adolescents.
Izkušenj pri otrocih in mladostnikih ni.
LIFE Study
Študija LIFE
When you begin treatment with this medication, you should not perform tasks which may require special attention (for example, driving an automobile or operating dangerous machinery) until you know how you tolerate your medicine.
Na začetku zdravljenja s tem zdravilom ne opravljajte opravil, ki zahtevajo posebno pozornost (na primer vožnje avtomobila ali upravljanje nevarnih strojev) dokler ne veste, kako zdravilo prenašate.
75114 Paris Cedex 08 France
75114 Paris Cedex 08 Francija
LABORATÓRIO MEDINFAR, Produtos Farmacêuticos, SA Rua Manuel Ribeiro de Pavia, 1-1° Venda Nova
Portugalska LABORATÓRIO MEDINFAR, Produtos Farmacêuticos, SA Rua Manuel Ribeiro de Pavia, 1-1° Venda Nova
Dosage adjustment of the antidiabetic drug may be required.
Lahko je potrebna prilagoditev odmerka antidiabetičnega zdravila.
However, if you miss a dose, do not take an extra dose.
Če izpustite odmerek, ne vzemite dvojnega odmerka.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF COZAAR COMP. AND ASSOCIATED NAMES (SEE ANNEX I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA COZAAR COMP. IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
If symptomatic hypotension should occur, supportive treatment should be instituted.
Če bi se pojavila simptomatska hipotenzija, je potrebno podporno zdravljenje.
Skanstes street 13, LV-1013, Riga, Latvia
Skanstes street 13, LV-1013, Riga, Latvija
These patients (9.4%) would have been over-treated on a FDC on a long term basis.
Ti bolniki (9,4 %) bi bili v primeru dolgotrajnega zdravljenja s fiksno kombinacijo odmerkov prekomerno zdravljeni.
In case of an overdose, contact your doctor immediately so that medical attention may be given promptly.
V primeru prevelikega odmerjanja, se takoj posvetujte z zdravnikom, da lahko takoj dobite ustrezno zdravniško pomoč.
You are advised not to drink alcohol whilst taking these tablets: alcohol and Cozaar Comp tablets may increase each other's effects.
Svetujemo vam, da med zdravljenjem s temi tabletami ne pijete alkohola: alkohol in zdravilo Cozaar Comp lahko povečata učinek drug drugega.
Given that the paediatric worksharing group is still ongoing, a definite working can only be implemented with respecto to studies in children and adolescents after the procedure is finalised.
Ker pediatrična delovna skupina še izvaja svoje delo, se lahko dokončna oblika dela glede študij pri otrocih in mladostnikih vnese šele po dokončanju postopka.
This medicinal product is authorized in the Member States of the EEA under the following names:
To zdravilo je v državah članicah EGP odobreno pod naslednjimi imeni: Avstrija
Frosst Portuguesa - Produtos Farmacêuticos, Lda.
Portugalska Frosst Portuguesa - Produtos Farmacêuticos, Lda.
Heptafarma- Companhia Farmacêutica, Sociedade Unipessoal, Lda
Portugalska Heptafarma- Companhia Farmacêutica, Sociedade Unipessoal, Lda
- the CHMP concluded that the Marketing Authorisation could be harmonised on the following indication:
- je CHMP zaključil, da je mogoče dovoljenje za promet z zdravilom uskladiti za naslednjo indikacijo:
Tatoiou Street, Nea Erythraia 14671, Greece
Tatoiou Street, Nea Erythraia 14671, Grčija
Electrolyte imbalances
Elektrolitska neravnovesja
- The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders have been assessed based on the documentation submitted and the scientific discussion within the Committee.
- so bili povzetki glavnih značilnosti zdravila, označevanje in navodila za uporabo, ki so jih predlagali imetniki dovoljenja za promet z zdravilom, ovrednoteni na podlagi predložene dokumentacije in znanstvene razprave znotraj Odbora,
It may harm them, even if their symptoms are the same as yours.
• škodovalo, čeprav imajo znake bolezni, podobne vašim.
• if you take diuretics (water pills)
• če jemljete diuretike (tablete za odvajanje vode).
Your doctor will decide on the appropriate dose of Cozaar Comp depending on your condition and whether you are taking other medicines.
Zdravnik vam bo predpisal ustrezen odmerek zdravila Cozaar Comp glede na vaše stanje in glede na to, ali jemljete še katera druga zdravila.
28027 MADRID
28027 MADRID, Španija
Due to the divergent national decisions taken by Member States concerning the authorisation of the above-mentioned products (and its associated names), Denmark notified the CHMP/EMEA Secretariat of an official referral under Article 30 of Directive 2001/83/EC as amended in order to resolve divergences amongst the nationally authorised SPCs and thus to harmonise its divergent SPCs across the EU.
Zaradi razhajajočih se odločitev na državni ravni, ki so jih sprejele države članice glede odobritve zgoraj navedenih zdravil (in z njimi povezanih imen), je Danska obvestila sekretariat CHMP/EMEA o uradnem napotitvenem postopku v skladu s členom 30 Direktive 2001/83/ES, kakor je bila spremenjena, da bi tako razrešila razhajanja med državno odobrenimi povzetki glavnih značilnosti zdravila in s tem uskladila razhajajoče se povzetke glavnih značilnosti zdravila po vsej EU.
00191 Rome, Italy
00191 Rim, Italija
- the CHMP concluded that the data are not supportive of the following indications and therefore they should be removed from the marketing authorisation:
- je CHMP zaključil, da podatki ne podpirajo naslednjih indikacij, ki jih je treba zaradi tega umakniti:
Patients with a history of angiooedema (swelling of the face, lips, throat, and/or tongue) should be closely monitored (see section 4.8).
Bolnike, ki so kdaj imeli angioedem (otekanje obraza, ustnic, žrela in/ali jezika) je treba pozorno spremljati (glejte poglavje 4.8).
Rare (more than 1 out of 10000 patients and less than 1 out of 1000 patients) • Hepatitis (inflammation of the liver), abnormal liver function tests
Redki (pojavijo se pri več kot 1 od 10.000 ter manj kot 1 od 1.000 bolnikov): • hepatitis (vnetje jeter), nenormalni izvidi delovanja jeter
The CHMP considered that the text concerning pregnancy and lactation in the SPC (sections 4.3, 4.4 and 4.6) should be amended to include the outcome of the PhVWP report on ACE Inhibitors and angiotensin II receptors antagonists (AIIRAs) and recommendations on the use during the first trimester of pregnancy (EMEA/CHMP/PhVWP/474692/2007).
CHMP je menil, da je treba besedilo glede nosečnosti in dojenja v povzetku glavnih značilnosti zdravila (poglavja 4.3, 4.4 in 4.6) spremeniti, tako da bodo vključevala rezultate poročila PhVWP o zaviralcih ACE in antagonistih receptorjev za angiotenzin II (AIIRA-ji) ter priporočila o uporabi v prvem tromesečju nosečnosti (EMEA/CHMP/PhVWP/474692/2007).
In the losartan group 44% of the patients received HCTZ, in the atenolol group 38%.
V skupini, ki je prejemala losartan, je 44 % bolnikov prejemalo tudi HCTZ, v skupini, ki je prejemala atenolol, pa 38 %.
2700-547 Amadora, Portugal
2700-547 Amadora, Portugalska
Cozaar Comp. and Cozaar Comp Forte (losartan/hydrochlorothiazide) have been included in the list of products for Summary of Products Characteristics (SPC) harmonisation, drawn up by the CMD(h), in accordance with Article 30(2) of Directive 2001/83/EC, as amended.
Zdravili Cozaar Comp. in Cozaar Comp Forte (losartan/hidroklorotiazid) sta bili vključeni na seznam zdravil za uskladitev povzetka glavnih značilnosti zdravila (SPC), ki ga je pripravil CMD(h) v skladu s členom 30(2) Direktive 2001/83/ES, kakor je bila spremenjena.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.- viale Shakespeare 47, 00144 Rome, Italy
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.- viale Shakespeare 47 , 00144 Rim, Italija
Laboratory Test Interactions
Vpliv na laboratorijske teste
• if you need to have an anaesthetic (even at the dentist) or before surgery, or if you are going to have tests to check your parathyroid function, you must tell the doctor or medical staff that you are taking Losartan potassium and Hydrochlorothiazide tablets.
• če boste morali dobiti anestezijo (tudi pri zobozdravniku) ali boste operirani, ali greste na teste delovanja obščitnične žleze, morate zdravniku ali medicinskemu osebju povedati, da jemljete tablete s kalijevim losartanom in hidroklorotiazidom.
• as first step treatment in patients with moderate to severe hypertension and in patients with high or very high cardiovascular risk
• kot prvi korak pri zdravljenju bolnikov z zmerno do hudo hipertenzijo in pri bolnikih z visokim ali zelo visokim kardiovaskularnim tveganjem,
Carbamazepine Risk of symptomatic hyponatremia.
Karbamazepin Tveganje za simptomatsko hiponatriemijo.
In clinical studies of at least one year's duration, the antihypertensive effect was maintained with continued therapy.
V kliničnih študijah, ki so trajale vsaj eno leto, se je med rednim zdravljenjem antihipertenzivni učinek vzdrževal.
The mechanism of the antihypertensive effect of thiazide diuretics is not fully known.
Mehanizem antihipertenzivnega delovanja tiazidov ni popolnoma znan.
Both losartan and its principal active metabolite have a far greater affinity for the AT1 receptor than for the AT2 receptor.
Oba, losrtan in njegov osnovni aktivni presnovek, imata precej večjo afiniteto za AT1 receptor kot za AT2 receptor.
Characteristics in Patients
Značilnosti bolnikov
As with other medicines which affect the excretion of sodium, lithium excretion may be reduced.
Kot pri drugih zdravilih, ki vplivajo na izločanje natrija, se lahko zmanjša izločanje litija.
In addition, in an overall analysis of 16 double-blind clinical trials in 4131 patients, the incidence of spontaneously reported cough in patients treated with losartan was similar (3.1%) to that of patients treated with placebo (2.6%) or hydrochlorothiazide (4.1%), whereas the incidence with ACE inhibitors was 8.8%.
Poleg tega je skupna analiza 16 dvojno slepih kliničnih preizkušanj s 4.131 bolniki pokazala, da je bila pojavnost kašlja iz spontanih poročil pri bolnikih, zdravljenih z losartanom, podobna (3,1 %) kot pri bolnikih, ki so prejemali placebo (2,6 %) ali hidroklorotiazid (4,1 %), medtem ko je bila pojavnost pri zaviralcih ACE 8,8 %.
Other antihypertensive drugs Additive effect.
Druga antihipertenzivna zdravila Aditivni učinki.
In addition, a prevention indication for HCTZ alone, based on the LIFE data is not considered approvable.
Poleg tega se preventivna indikacija za samostojni HCTZ na podlagi podatkov iz študije LIFE ne upošteva kot primerna za odobritev.
Losartan has no effect on autonomic reflexes and no sustained effect on plasma norepinephrine.
Losartan nima učinka na avtonomne reflekse in nima trajnega učinka na količino noradrenalina v plazmi.
Therapy with Cozaar Comp should be discontinued and the patient observed closely.
Zdravljenje z zdravilom Cozaar Comp je treba prekiniti in bolnika pozorno opazovati.
Hypotension and electrolyte/fluid imbalance
Hipotenzija ter neravnovesja elektrolitov/tekočin
You should not take Cozaar Comp in the first 12 weeks of pregnancy, and you must not take them at all after the 13th week as their use during pregnancy may possibly be harmful to the baby.
Zdravila Cozaar Comp naj se v prvih 12 tednih nosečnosti ne bi jemalo, od 13. tedna dalje pa je njegova uporaba celo prepovedana, ker lahko škoduje otroku.
Overdosage can cause a drop in blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration.
Prevelik odmerek lahko povzroči padec krvnega tlaka, palpitacije, počasen utrip, spremembe v sestavi krvi in dehidracijo.
Cozaar Comp is indicated for the treatment of essential hypertension (high blood pressure).
Zdravilo Cozaar Comp je indicirano za zdravljenje esencialne hipertenzije (visokega krvnega tlaka).
Losartan has been shown to have a mild and transient uricosuric effect.
Losartan ima blag in prehoden urikozurični učinek.
Therefore, losartan/hydrochlorothiazide should not be administered to children and adolescents.
Zato se losrtan/hidroklorotiazid pri otrocih in mladotnikih ne sme uporabljati.
• if you have severely impaired kidney function or your kidneys are not producing any urine.
• če imate hudo okvaro ledvic ali vaše ledvice ne tvorijo urina.
The main areas of disharmony of the existing Summary of Product Characteristics were section 4.1 Therapeutic Indications, section 4.3 Contraindications, and section 4.4 Special Warnings and Precautions for Use.
Glavna področja neskladnosti v obstoječem povzetku glavnih značilnosti zdravila so bila poglavje 4.1 Terapevtske indikacije, poglavje 4.3 Kontraindikacije ter poglavje 4.4 Posebna opozorila in previdnostni ukrepi.
Periodic determination of serum electrolytes should be performed at appropriate intervals in such patients.
Pri teh bolnikih je treba v primernih intervalih periodično spremljati elektrolite v serumu.
Cozaar Comp should not be initiated during pregnancy.
Zdravljenja z zdravilom Cozaar Comp se ne sme začeti med nosečnostjo.
6.6 Special precautions for disposal <and other handling> No special requirements.
6.6 Posebni varnostni ukrepi za odstranjevanje Nobenih posebnih zahtev.
Thiazides should be discontinued before carrying out tests for parathyroid function.
Jemanje tiazidov je treba prekiniti pred izvedbo testov paratiroidne funkcije.
A recent review in the BMJ shows that specifically the preventive effect on stroke of atenolol is lower than for other antihypertensives; RR of 1.26 (95%CI: 1.15 to 1.38).
Nedavno poročilo, ki je bilo objavljeno v BMJ, kaže, da je preventivni učinek atenolola na možgansko kap manjši kot pri drugih zdravilih proti hipertenziji; RR od 1,26 (95 % CI: 1,15 do 1,38).
Therefore, the use of Cozaar Comp tablets is not recommended.
Zato uporabe tablet Cozaar Comp ne priporočamo.
Next to these effects, there are further adverse reactions reported after the introduction of the product to the market as follows:
Poleg teh učinkov, so po prihodu zdravila na trg poročali še o naslednjih neželenih učinkih:
• 2nd and 3rd trimester of pregnancy (see section 4.4 and 4.6)
• 2. in 3. trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine (see section 6.1).
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze tega zdravila ne smejo jemati (glejte poglavje 6.1).
Cozaar Comp works equally well in and is equally well tolerated by most older and younger adult patients.
Zdravilo Cozaar Comp enako dobro deluje pri večini starejših in mlajših bolnikov.
Increase in dosage of probenecid or sulfinpyrazone may be necessary.
Morda je treba povečati odmerke probenecida ali sulfinpirazona.
Pressor amines (e.g., adrenaline) Possible decreased response to pressor amines but not sufficient to preclude their use.
Presorni amini (npr. adrenalin) Možna je zmanjšana odzivnost na presorske amine, vendar ne toliko, da bi to oviralo njihovo uporabo.
The CHMP was concerned that there is no evidence that supports each of the two substances in Cozaar Comp (losartan and HCTZ) having a documented contribution to the claimed indication as required by the The NfG on fixed dose combination products.
CHMP je izrazil zaskrbljenost glede odsotnosti dokazov, ki bi podpirali dokumentiran prispevek vsake od dveh snovi v zdravilu Cozaar Comp (losartan in HCTZ), kot to zahteva NfG o zdravilih s fiksno kombinacijo odmerkov.
The antihypertensive effect of Cozaar Comp is sustained for a 24-hour period.
Antihipertenzivni učinek zdravila Cozaar Comp se vzdržuje 24 ur.
There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.
Poročali so o posameznih primerih hemolitične anemije pri sočasni uporabi hidroklorotiazida in metildope.
The MAH was asked to provide data on safety and efficacy for these subgroups of patients (Losartan, Atenolol, Losartan + HCTZ, Atenolol + HCTZ) in order to gain more insight into the contribution of HCTZ to the overall benefit risk ratio.
Od imetnika dovoljenja za promet z zdravilom so zahtevali podatke o varnosti in učinkovitosti pri omenjenih podskupinah bolnikov (losartan, atenolol, losartan + HCTZ, atenolol + HCTZ), da bi z njimi dobili boljši vpogled v prispevek, ki ga ima HCTZ na skupno razmerje med koristnimi učinki in tveganjem.
Angiotensin II, a potent vasoconstrictor, is the primary active hormon of the renin-angiotensin system and an important determinant of the pathophysiology of hypertension.
Angiotenzin II, močan vazokonstriktor, je primarni aktivni hormon sistema renin/angiotenzin in pomemben faktor v patofiziologiji hipertenzije.
Furthermore, losartan does not inhibit ACE (kininase II), the enzyme that degrades bradykinin.
Nadalje, losartan ne zavira ACE (kininaze II), encima, ki razgrajuje bradikinin.